Fresolimumab  (Synonyms: GC1008)

Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease^[1][2][3][4].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

TGFB1

Fresolimumab (10-3000 μg/kg; i.v.; single administration) requires a high dose (3 mg/kg) to obtain a statistically significant inhibitory effect in Bleomycin (HY-108345)-induced acute lung injury rats, inhibiting inflammatory cell infiltration, lung tissue damage^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7040  [NCBI]

P01137

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.4 kDa

948564-73-6

Liquid

Colorless to light yellow

[Fresolimumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized TGF beta 1/TGFB1 Protein, Human can bind Fresolimumab. The EC₅₀ for this effect is 67.28 ng/mL.
• 
  Flow Cytometry analysis of PC-3 cells labelling TGFB1 (red) with Fresolimumab (anti-TGFB1) (HY-P99020). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 kappa (HY-P99003). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Song IW, et al. Targeting TGF-β for treatment of osteogenesis imperfecta. J Clin Invest. 2022 Apr 1;132(7):e152571.  [Content Brief]

  [2]. Lan Y, et al. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. J Immunother Cancer. 2022 Jul;10(7):e004122.  [Content Brief]

  [3]. Oude Munnink TH, et al. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011 Dec;52(12):2001-8.  [Content Brief]

  [4]. Kadam AH, et al. Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy. PLoS One. 2022 Nov 22;17(11):e0276462.  [Content Brief]